NCT01436214View on ClinicalTrials.gov

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2017

Conditions
Prostate Cancer
Interventions
DRUG

APC-100

Daily oral, dose escalation, 28-day cycle(s)

Trial Locations (2)

48201

Karmanos Cancer Institute, Detroit

53705

University of Wisconsin Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
lead

Adamis Pharmaceuticals Corporation

INDUSTRY

NCT01436214 - Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | Biotech Hunter | Biotech Hunter